Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening.

Kolokoltsov AA, Saeed MF, Freiberg AN, Holbrook MR, Davey RA.

Drug Dev Res. 2009 Jun 1;70(4):255-265.

2.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
4.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
5.

FGI-104: a broad-spectrum small molecule inhibitor of viral infection.

Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, Luo G, Nelson EA, Li L, Huang Z, Murray M, Ellis WY, Hensley L, Christopher-Hennings J, Olinger GG, Goldblatt M.

Am J Transl Res. 2009 Jan 5;1(1):87-98.

6.

Host factors mediating HIV-1 replication.

Friedrich BM, Dziuba N, Li G, Endsley MA, Murray JL, Ferguson MR.

Virus Res. 2011 Nov;161(2):101-14. doi: 10.1016/j.virusres.2011.08.001. Epub 2011 Aug 18. Review.

PMID:
21871504
7.

Kinome siRNA screen identifies novel cell-type specific dengue host target genes.

Kwon YJ, Heo J, Wong HE, Cruz DJ, Velumani S, da Silva CT, Mosimann AL, Duarte Dos Santos CN, Freitas-Junior LH, Fink K.

Antiviral Res. 2014 Oct;110:20-30. doi: 10.1016/j.antiviral.2014.07.006. Epub 2014 Jul 18.

PMID:
25046486
8.

Identification of an antioxidant small-molecule with broad-spectrum antiviral activity.

Panchal RG, Reid SP, Tran JP, Bergeron AA, Wells J, Kota KP, Aman J, Bavari S.

Antiviral Res. 2012 Jan;93(1):23-9. doi: 10.1016/j.antiviral.2011.10.011. Epub 2011 Oct 18.

PMID:
22027648
9.

Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus.

Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA.

PLoS Pathog. 2008 Aug 29;4(8):e1000141. doi: 10.1371/journal.ppat.1000141.

10.

Treatment of ebola virus disease.

Kilgore PE, Grabenstein JD, Salim AM, Rybak M.

Pharmacotherapy. 2015 Jan;35(1):43-53. doi: 10.1002/phar.1545. Review.

PMID:
25630412
11.

Therapeutic targets for HIV-1 infection in the host proteome.

Liang WS, Maddukuri A, Teslovich TM, de la Fuente C, Agbottah E, Dadgar S, Kehn K, Hautaniemi S, Pumfery A, Stephan DA, Kashanchi F.

Retrovirology. 2005 Mar 21;2:20.

12.

Gene expression signature-based screening identifies new broadly effective influenza a antivirals.

Josset L, Textoris J, Loriod B, Ferraris O, Moules V, Lina B, N'guyen C, Diaz JJ, Rosa-Calatrava M.

PLoS One. 2010 Oct 4;5(10). pii: e13169. doi: 10.1371/journal.pone.0013169.

13.

FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG.

Sci Transl Med. 2013 Jun 19;5(190):190ra79. doi: 10.1126/scitranslmed.3005471.

14.

Human subtilase SKI-1/S1P is a master regulator of the HCV Lifecycle and a potential host cell target for developing indirect-acting antiviral agents.

Olmstead AD, Knecht W, Lazarov I, Dixit SB, Jean F.

PLoS Pathog. 2012 Jan;8(1):e1002468. doi: 10.1371/journal.ppat.1002468. Epub 2012 Jan 5.

15.

Retinazone inhibits certain blood-borne human viruses including Ebola virus Zaire.

Kesel AJ, Huang Z, Murray MG, Prichard MN, Caboni L, Nevin DK, Fayne D, Lloyd DG, Detorio MA, Schinazi RF.

Antivir Chem Chemother. 2014 Apr 11;23(5):197-215. doi: 10.3851/IMP2568.

PMID:
23636868
16.

Identification of novel host-oriented targets for Human Immunodeficiency Virus type 1 using Random Homozygous Gene Perturbation.

Mao H, Chen H, Fesseha Z, Chang S, Ung-Medoff H, Van Dyke J, Kohli M, Li WB, Goldblatt M, Kinch MS.

Virol J. 2009 Sep 29;6:154. doi: 10.1186/1743-422X-6-154.

17.

The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses.

Pécheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, Mire CE, Kawaoka Y, Geisbert TW, Polyak SJ.

J Virol. 2016 Jan 6;90(6):3086-92. doi: 10.1128/JVI.02077-15.

18.

A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity.

Watt A, Moukambi F, Banadyga L, Groseth A, Callison J, Herwig A, Ebihara H, Feldmann H, Hoenen T.

J Virol. 2014 Sep;88(18):10511-24. doi: 10.1128/JVI.01272-14. Epub 2014 Jun 25.

19.

[Aiming for zero blindness].

Nakazawa T.

Nippon Ganka Gakkai Zasshi. 2015 Mar;119(3):168-93; discussion 194. Review. Japanese.

PMID:
25854109
20.

Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis.

Murray JL, McDonald NJ, Sheng J, Shaw MW, Hodge TW, Rubin DH, O'Brien WA, Smee DF.

Antivir Chem Chemother. 2012 May 14;22(5):205-15. doi: 10.3851/IMP2080.

PMID:
22374988

Supplemental Content

Support Center